Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAROSTEP
NCT06660862Phase 4Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Nov 2026
- Primary completion
- Nov 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of darolutamide in prostate cancer (PCa), sponsored by University of Chicago. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06660862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660862.